TrialsgrambetaRCTs are beautiful

2023 ESC Guidelines for the management of acute coronary syndromes

This guideline cites 18 of the 199 landmark trials in our Cardiology register.

The 2023 ESC Guidelines unify STEMI and NSTE-ACS into a single acute coronary syndrome pathway, covering reperfusion, antithrombotic therapy, revascularisation and secondary prevention. This page maps the landmark trials from our register that the guideline cites — grouped by theme.

Antithrombotic & antiplatelet therapy7

  • 2019ISAR-REACT 5⁠Cardiology · Coronary · AntiplateletsIn 4,018 patients with acute coronary syndromes managed invasively, prasugrel reduced death, MI or stroke at one year compared with ticagrelor.HR 1.36Read →
  • 2019AUGUSTUS Core⁠Cardiology · Thrombosis · AF + PCIIn 4,614 patients with AF and recent ACS or PCI, apixaban without aspirin reduced major or clinically relevant bleeding compared with warfarin-based triple therapy.Read →
  • 2013WOEST⁠Cardiology · Thrombosis · AF + PCIIn 573 patients on oral anticoagulation undergoing PCI, clopidogrel without aspirin reduced bleeding compared with triple therapy.HR 0.36Read →
  • 2009PLATO Core⁠Cardiology · Coronary · AntiplateletsIn 18,624 patients hospitalised with ACS, ticagrelor reduced CV death, MI or stroke compared with clopidogrel, with similar major bleeding.HR 0.84Read →
  • 2007TRITON-TIMI 38⁠Cardiology · Coronary · AntiplateletsIn 13,608 ACS patients undergoing planned PCI, prasugrel reduced ischaemic events but increased major bleeding relative to clopidogrel.HR 0.81Read →
  • 2005COMMIT⁠Cardiology · Coronary · clopidogrelIn 45,852 patients with acute myocardial infarction, clopidogrel added to aspirin reduced death, reinfarction, or stroke compared with placebo.9.2% vs 10.1%Read →
  • 2001CURE Core⁠Cardiology · Coronary · AntiplateletsIn 12,562 patients with NSTE-ACS, clopidogrel plus aspirin reduced the composite of CV death, MI or stroke versus aspirin alone.RR 0.8Read →

Reperfusion & revascularisation3

  • 2019COMPLETE⁠Cardiology · Coronary · RevascularisationIn 4,041 STEMI patients with multivessel disease, staged complete revascularisation reduced CV death or MI compared with culprit-lesion-only PCI.HR 0.74Read →
  • 2017CULPRIT-SHOCK Core⁠ICU · CS / MCS · RevascularisationIn 706 patients with multivessel disease and cardiogenic shock, culprit-only PCI with staged completion reduced 30-day death or RRT compared with immediate multivessel PCI.RR 0.83Read →
  • 1988ISIS-2 Core⁠Cardiology · Coronary · ReperfusionIn 17,187 patients with suspected acute myocardial infarction, aspirin plus intravenous streptokinase reduced 5-week vascular mortality compared with placebo.8.0% vs 13.2%Read →

Lipid-lowering & secondary prevention6

  • 2019REDUCE-IT⁠Cardiology · Lipids · TriglyceridesIn 8,179 statin-treated patients with high triglycerides, icosapent ethyl reduced major adverse cardiovascular events compared with placebo.HR 0.75Read →
  • 2018ODYSSEY OUTCOMES⁠Cardiology · Lipids · PCSK9 inhibitorIn 18,924 patients with recent acute coronary syndrome on high-intensity statin, alirocumab reduced major adverse cardiovascular events compared with placebo (HR 0.85, 95% CI 0.78-0.93).HR 0.8595% CI 0.78-0.93Read →
  • 2017FOURIER⁠Cardiology · Lipids · PCSK9iIn 27,564 patients with ASCVD on statins, evolocumab reduced CV death, MI, stroke, hosp UA or revasc compared with placebo.HR 0.8595% CI 0.79-0.92Read →
  • 2017COMPASS⁠Cardiology · Thrombosis · Chronic atherosclerosisIn 27,395 patients with stable coronary or peripheral artery disease, low-dose rivaroxaban plus aspirin reduced cardiovascular death, stroke or MI compared with aspirin alone.HR 0.76Read →
  • 2015IMPROVE-IT⁠Cardiology · Lipids · Non-statin LDLIn 18,144 patients post-ACS, ezetimibe added to simvastatin further reduced CV death, MI, UA, revasc or stroke compared with simvastatin alone.HR 0.94Read →
  • 2004PROVE-IT⁠Cardiology · Lipids · StatinsIn 4,162 patients after acute coronary syndrome, intensive atorvastatin 80 mg reduced death or major cardiovascular events compared with moderate pravastatin 40 mg (16% relative reduction, P=0.005).22.4% vs 26.3%Read →

Post-cardiac-arrest care2

  • 2021TTM2 Core⁠Cardiology · Critical care · Temperature managementIn 1,861 unconscious adults after OHCA, hypothermia at 33 °C did not reduce all-cause mortality at 6 months compared with targeted normothermia (≤ 37.5 °C).RR 1.04Read →
  • 2013TTM⁠Cardiology · Critical care · Temperature managementIn 939 unconscious survivors of out-of-hospital cardiac arrest, targeted temperature of 33 °C did not improve survival or neurological outcome compared with 36 °C.HR 1.06Read →

Cited landmark trials not yet in the register7

Further landmark trials this guideline cites that are not (yet) covered in our register. Each links out to the study for further reading.

Every trial shown is one this guideline actually cites: each link was checked against the guideline's own reference list, and the few that a machine cannot match, a trial cited through a later follow-up, or a NICE guideline, which carries no DOI, were verified by hand against the full text. This is not the guideline's complete reference list, only the landmark trials it cites that our register holds.